SPIDIA-RNA: First external quality assessment for the pre-analytical phase of blood samples used for RNA based analyses

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F13%3A00392025" target="_blank" >RIV/86652036:_____/13:00392025 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.ymeth.2012.10.007" target="_blank" >http://dx.doi.org/10.1016/j.ymeth.2012.10.007</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ymeth.2012.10.007" target="_blank" >10.1016/j.ymeth.2012.10.007</a>

Jazyk výsledku

angličtina

Název v původním jazyce

SPIDIA-RNA: First external quality assessment for the pre-analytical phase of blood samples used for RNA based analyses

Popis výsledku v původním jazyce

The diagnostic use of in vitro molecular assays can be limited by the lack of guidelines for collection, handling, stabilization and storage of patient specimens. One of the major goals of the EC funded project SPIDIA (www.spidia.eu) is to develop evidence-based quality guidelines for the pre-analytical phase of blood samples used for molecular testing which requires intracellular RNA analytes. To this end, a survey and a pan-European external quality assessment (EQA) were implemented. This report is the summary of the results of that trial. With the European Federation of Laboratory Medicine (EFLM) support, 124 applications for participation in the trial were received from 27 different European countries, and 102 laboratories actually participated inthe trial. Each participating laboratory described their respective laboratory policies and practices as well as blood collection tubes typically used in performing this type of testing. The participating laboratories received two identic

Název v anglickém jazyce

SPIDIA-RNA: First external quality assessment for the pre-analytical phase of blood samples used for RNA based analyses

Popis výsledku anglicky

The diagnostic use of in vitro molecular assays can be limited by the lack of guidelines for collection, handling, stabilization and storage of patient specimens. One of the major goals of the EC funded project SPIDIA (www.spidia.eu) is to develop evidence-based quality guidelines for the pre-analytical phase of blood samples used for molecular testing which requires intracellular RNA analytes. To this end, a survey and a pan-European external quality assessment (EQA) were implemented. This report is the summary of the results of that trial. With the European Federation of Laboratory Medicine (EFLM) support, 124 applications for participation in the trial were received from 27 different European countries, and 102 laboratories actually participated inthe trial. Each participating laboratory described their respective laboratory policies and practices as well as blood collection tubes typically used in performing this type of testing. The participating laboratories received two identic

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Methods

ISSN

1046-2023

e-ISSN

—

Svazek periodika

59

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

20-31

Kód UT WoS článku

000314555700004

EID výsledku v databázi Scopus

—